Needham initiated GE HealthCare coverage with a Buy rating and a $93 target, implying about 44% upside from the stock’s Sept. 21 close of $64.81. Analyst David Saxon said shares reflected a bear-case outlook after falling about 20% since January.
Needham’s $93 target values GE HealthCare at 17 times its projected 2027 earnings, versus about 12.6 times currently and 18.8 times for peers. The firm forecasts 4%–6% sales growth and 7%–9% profit growth over the next 12 months, and expects its Advanced Imaging Solutions division to accelerate by 2027. TheStreet data cited in the article show 10 of 15 analysts covering the stock rate it Buy, with a consensus target of $80.
Tariffs, Chinese hospitals temporarily halting new scanning-equipment purchases and weak first-half results at Patient Care Solutions (PCS) weighed on the stock; PCS is under strategic review. CFO Jay Saccaro said tariffs accounted for about half of the year-over-year gross-margin decline, which the company was offsetting with pricing and cost measures. GE HealthCare is scheduled to report third-quarter 2026 results on Oct. 30, with investors watching for updates on China orders, the PCS review and margins.
